Company Overview and News

0
Medibio Receives TGA Approval

39m globenewswire
SYDNEY, Australia and MINNEAPOLIS, June 19, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company, announced today it has received confirmation that the Company’s Depression Diagnostic Aide (DDA) and Mental Health Monitoring Platform (MHM) have been included on the register of Australian Therapeutic Goods Administration (ATGA). Medibio’s DDA and MHM technology underpin the Company’s Mental Index application and Logics platform.
MEB

0
Medibio Broadens Opportunities with Compatibility to Fitbit Wearable Devices for Mental Health Measurement

2018-06-13 globenewswire
SYDNEY, Australia and MINNEAPOLIS, June 13, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (ASX:MEB) (OTCQB:MDBIF), the world leader in objective measurement technology for mental health, has recently enhanced the compatibility of its mobile app product to accept data from Fitbit devices equipped with heart rate monitors.
MEB

16
Medibio Announces Next Tranche of Corporate Health Contracts

2018-05-10 globenewswire
SYDNEY, Australia and MINNEAPOLIS, May 09, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB) (OTCQB:MDBIF), a mental health technology company, is pleased to confirm the next tranche of corporate clients to join the Company’s Corporate Mental Health Check-in.
RTPPF RIO RIO MEB RIO RTNTF

0
Medibio Corporate Health contract signed with Australia’s 3rd largest private healthcare provider

2018-05-09 globenewswire
SYDNEY, Australia and MINNEAPOLIS, May 08, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, today announced the execution of a commercial contract with St. John of God Health Care (SJGHC) to deploy Medibio’s new product for its newly established Corporate Health division.
MEB

0
Medibio Receives CE Certification

2018-05-03 globenewswire
SYDNEY, Australia and MINNEAPOLIS, May 02, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company, is pleased to confirm it has received CE (Conformité Européenne) Marking certification for its first release technology product and platform.
MEB

0
Medibio Launches Global Corporate Mental Health Product

2018-05-01 globenewswire
SYDNEY, Australia and MINNEAPOLIS, April 30, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company)(ASX:MEB)(OTCQB:MDBIF), a mental health technology company confirms the launch and release of the Company’s Corporate Mental Health for business product and platform (the Platform).
MEB

0
Medibio Announces Scientific Advisory Board

2018-04-26 globenewswire
SYDNEY, Australia and MINNEAPOLIS, April 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company confirms establishment of its Scientific Advisory Board (SAB).
MEB MLPH

0
Medibio shares rise following recent acquisition of Vital Conversations

2018-04-09 proactiveinvestors.com.au
Medibio Ltd (ASX:MEB), a mental health technology company, is one of the top performing companies on the ASX today with its shares trading up 30% to 19.5 cents after midday.
MEB

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:MEB / MEDIBIO LIMITED on message board site Silicon Investor.

$2 or higher gas - Can ethanol make a comeback? Donu0027t abuse it, reuse it! ARCI makes the big comeback.
BOILER ROOM OPERATOR BRYANT CRAGUN MAKES COMEBACK. Beaten-down Stocks Ready For A Comeback
SWMCF- Making a comeback this week. Macromedia...making a comeback?
WTZRA -Weitzer Homebuilders Inc/Century Ptnrs. Low float!! Applied Theory ( ATHY ) - looking for a big comeback
TMBT - Timebeat.com Enterprises Inc. (OTC BB: TMBT) HOMEBASE (HBI)